GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (OTCPK:SYGGF) » Definitions » Short Percentage of Float

SYGGF (Synairgen) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is Synairgen Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Synairgen's Short Percentage of Float

For the Biotechnology subindustry, Synairgen's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synairgen's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synairgen's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Synairgen's Short Percentage of Float falls into.


;
;

Synairgen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (OTCPK:SYGGF) » Definitions » Short Percentage of Float
Comparable Companies
XTER:MDG1 STU:T9G VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392
Traded in Other Exchanges
OMY:Germany
Address
Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD
Website
https://www.synairgen.com
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.